London-based ScienceMachine secured €2.9 million in a pre-Seed funding round. Revent and Nucleus Capital led the investment. This funding supports the company's BioTech data analysis AI.
ScienceMachine develops AI agents for BioTech and pharma data analysis. Its flagship product, Sam, functions as an autonomous AI bioinformatician. Sam helps scientists extract insights faster and more accurately. This addresses the challenge of overwhelming biological data and limited data scientists in life sciences. Many discoveries face delays without such tools.
Sam integrates with existing databases and lab workflows. It continuously processes experimental data. The AI agent identifies patterns, insights, and potential breakthroughs without manual intervention. This provides researchers with output typically requiring an entire data science team. Early customers report faster results at lower costs.
Fueling Advanced BioTech AI Analysis
ScienceMachine operates with a two-person team. The company automates internal work using AI. This approach allows them to outpace larger teams. They launched a fully autonomous AI agent already in use by BioTech customers. Unlike companies such as BenevolentAI or Exscientia, ScienceMachine achieved production-level AI automation without initial marketing spend.
One month post-launch, ScienceMachine secured multiple contracts. A fast-growing pipeline developed without marketing investment. This demonstrates significant market traction for their BioTech funding solution.
The new capital will support product development. ScienceMachine also plans hiring, focusing on sales and pharma partnerships. The company aims to expand its reach beyond BioTech startups. Future targets include larger pharmaceutical companies needing scalable AI healthcare startups solutions. This expansion seeks higher annual contract values.
